NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
2024年5月7日 - 9:00PM
ビジネスワイヤ(英語)
Ordered product sales of Avenova®-branded
products on Amazon.com set back-to-back records in March and April
2024
Enhanced marketing program provides potential
for additional growth in the U.S. dry eye disease treatment market
projected to reach nearly $5 billion by 2030
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare and wound care
products, announces record ordered product sales during the month
of April for its Avenova-branded eyecare products on Amazon.com,
the Company’s largest sales channel. Sales through Amazon for April
2024 increased by more than 20% compared with April 2023.
“We are very excited about our progress with ordered product
sales for Avenova on Amazon, including setting a record for ordered
product sales in March and then immediately beating that record in
April. Ordered product sales in the previous two months have even
eclipsed prior months that included record sales days during Prime
Day events,” said Justin Hall, CEO of NovaBay. “This success
follows the streamlining of our business to focus solely on eyecare
and the launch of our enhanced marketing programs. We attribute
these unparalleled sales months to the high quality of our Avenova
products and the effectiveness of those cost-efficient marketing
programs. We see ample room for additional growth with the U.S.
market for the treatment of dry eye disease projected to reach
nearly $5 billion by 2023.”
NovaBay offers best-in-class Avenova-branded products for each
step of the standard dry-eye treatment regimen, including Avenova
Antimicrobial Lid & Lash Solution, the No. 1 doctor-recommended
lid and lash cleanser, lubricating eye drops for instant relief, a
warm eye compress to soothe, an antioxidant-rich dietary supplement
with omega-3 oils and the i-Chek to monitor physical eyelid
health.
About NovaBay Pharmaceuticals, Inc.
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash
Solution is often prescribed by eyecare professionals for
blepharitis and dry eye disease and is available directly to
consumers through online distribution channels such as Amazon.com.
It is clinically proven to kill a broad spectrum of bacteria to
help relieve the symptoms of bacterial dry eye, yet is
non-irritating and completely safe for regular use. In addition to
this Avenova OTC product line, NovaBay offers the Avenova
Allograft, an amniotic tissue prescription-only product, is
available through eyecare professionals in the United States.
Forward-Looking Statements
This release contains information about management's view of the
Company's future expectations, plans and prospects that constitute
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the fact that they
do not relate strictly to historic or current facts. Such
forward-looking statements are based upon management’s current
expectations, assumptions, estimates, projections and beliefs.
These statements include, but are not limited to, statements
regarding our business strategies, commercial progress, current and
potential future sales channels, and any future revenue, and the
timing of such revenue, that may result from these marketing
efforts, as well as generally the Company’s expected future
financial results. These statements involve risks, uncertainties
and other factors that may cause actual results or achievements to
be materially different and adverse from those expressed in or
implied by these forward-looking statements. Factors that might
cause or contribute to such differences include, but are not
limited to, risks and uncertainties relating to the size of the
potential market for our products, the Company’s products not being
able to penetrate one or more targeted markets and the Company’s
ability to continue as a going concern and revenues (or the
execution on capital raise opportunities) not being sufficient to
meet the Company’s cash needs. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-K/Q
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on X
Connect with NovaBay on LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507490272/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com Investor
Contact LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 4 2024 まで 5 2024
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 5 2023 まで 5 2024